Abbott, J&J: tops in sales force quality

Share this article:
Abbott Laboratories, followed by Johnson & Johnson and Eli Lilly, were ranked the top pharma companies in overall sales force quality by primary care physicians, according to TargetRx's “Sales Force Analysis” report. Genentech, followed by Novartis and TAP Pharmaceutical Products, were the top-ranked companies in overall sales force quality by specialty physicians, the report found.

The TargetRx analysis benchmarked 11 pharmaceutical sales forces that call on primary care physicians and 15 pharmaceutical sales forces that call on physician specialists against each other. 
Drawing conclusions based on 2005 performance and sales force effectiveness to physician prescribing, the analysis aims to provide pharma companies with opportunities to improve their market position, according to Mike Luby, TargetRx's CEO.

“We are not just polling physicians and telling pharmaceutical companies what physicians are saying about them,” Luby told MM&M. “With our patented approach, we are able to determine how things you are doing in the marketplace drive market share.” 

Key drivers of the TargetRx data included detail piece effectiveness, which measures how well the detail piece increases prescribing. 

“Schering-Plough really distinguishes itself in this area and is the top company on detail piece effectiveness,” Luby said. 

Another driver of data is identifying the appropriate patient for therapy. “Among primary care specialists, Lilly ranks No. 1 and Abbott ranks No. 2 in this category. Among specialty physicians, Abbott ranks No. 1 and Lilly ranks No. 2,” he explained.

Companies included in the benchmarking were Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Genentech, GlaxoSmithKline, Hoffman-La Roche, Johnson & Johnson, Merck, Novartis, Pfizer, Sanofi-Aventis, Schering-Plough, TAP and Wyeth. 
Share this article:

Email Newsletters

More in Features

Antidote: On Cystic Fibrosis treatments

Antidote: On Cystic Fibrosis treatments

Recent treatments in CF, including the inhaled antibiotic Tobramycin, have increased lifespan well into adulthood.

The $3 generic and the $1,000 pill: pharma outsiders just don't get it

The $3 generic and the $1,000 pill: pharma ...

What do you call the people who treat medical breakthroughs as if they were bank heists? Malicious? Uninformed? Not with it?

Leadership Exchange Uncut : The Agency-Client Relationship

Leadership Exchange Uncut : The Agency-Client Relationship

Click the above link to access MM&M's first Leadership Exchange Uncut e-book, "The Agency-Client Relationship"